Condition: Hepatocellular Carcinoma (HCC) · Sponsor: RayzeBio, Inc.
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
This description comes directly from the study's public registry record.
RayzeBio Clinical Trials · 1-619-657-0057 · clinicaltrials@rayzebio.com
Always discuss trial participation with your own doctor first.
| Research Facility | Birmingham, Alabama, United States | Recruiting |
| Research Facility | Phoenix, Arizona, United States | Recruiting |
| Research Facility | Tucson, Arizona, United States | Recruiting |
| Research Facility | Orange, California, United States | Recruiting |
| Research Facility | Jacksonville, Florida, United States | Recruiting |
| Research Facility | Lexington, Kentucky, United States | Recruiting |
| Research Facility | Baltimore, Maryland, United States | Recruiting |
| Research Facility | Rochester, Minnesota, United States | Recruiting |
| Research Facility | Omaha, Nebraska, United States | Recruiting |
| Research Facility | New York, New York, United States | Recruiting |
| Research Facility | Houston, Texas, United States | Recruiting |
| Research Facility | Charlottesville, Virginia, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06726161